Skip to main content
ALZN logo

Alzamend Neuro, Inc. (ALZN) Stock Price & Analysis

Alzamend Neuro, Inc. (ALZN) — MoonshotScore 32/100 (Weak band), calculated Nov 18, 2026. Price $1.02 (-3.77%), as of the Nov 19, 2026 trading session; market cap $4.92M.

Educational signal · not a buy or sell recommendation · How to read this

$1.02 −$0.04 (-3.77%) Market Cap $4.92M

Alzamend Neuro, Inc. · ALZN · NASDAQ

Alzamend Neuro, Inc. is an early clinical-stage biopharmaceutical company focused on developing novel treatments for neurodegenerative and psychiatric disorders.

Price as of Nov 19, 2026

Key Statistics

32 of 100

MoonshotScore v2 · Alzamend Neuro (ALZN)

Weak
Business Quality Thin (26)
Financial Safety Okay (49)
Valuation Fair (62)
Growth Durability Flat (40)
Momentum Quiet (45)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Weak quality, though the balance sheet and growth are only middling. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Okay; Valuation: Fair; Growth Durability: Flat; Momentum: Quiet.

  • EPS beat 5 of the last 8 reports
  • Altman Z -13.08 · Piotroski F 1

Holding back: weak fundamentals

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ALZN (57 recorded, newest six shown)
RecordedScoreBand
31Weak
31Weak
31Weak
31Weak
32Weak
32Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$1.02
Change on the day-3.77%
Market capitalisation$4.92M—
Shares traded on the day36.9K

Price & events

Other perspectives

Council score for Alzamend Neuro (ALZN): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Neutral
Valuation Moderate
Growth Durability Neutral
Momentum Neutral

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Neutral read

Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Strong
ROE Negative
Gross Margin Negative

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Alzamend Neuro (ALZN), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Alzamend Neuro, Inc. (ALZN) is listed on NASDAQ. It employs 4 people. The market values it at $4.92M.

2 · Latest results

What do the latest results show for Alzamend Neuro (ALZN)?

Short answer · as of

Against analyst estimates the company has EPS beat 5 of the last 8 reports.

3 · Financial strengths and risks

What are the financial strengths and risks for Alzamend Neuro (ALZN)?

Short answer · as of

What is holding it back is weak fundamentals. The distress and quality screens read Altman Z -13.08 · Piotroski F 1. Trailing ratios: current ratio 3.01 · earnings yield -163.8%.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -13.08 sits in the distress zone (elevated bankruptcy risk).
  • Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Alzamend Neuro (ALZN)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $0.00 · EPS -2.58 · 0 analysts.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No quarterly income statement is held for ALZN.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Alzamend Neuro compare with its peers?

Short answer

Alzamend Neuro's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.07 Nov 19, 2026$540M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.06 Nov 19, 2026$258M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.26 Nov 18, 2026$85.5M82 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.25 Nov 18, 2026$102M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.89 Nov 18, 2026$169M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.88 Nov 19, 2026$178M69 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$12.17 Nov 19, 2026$861M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.28 Nov 19, 2026$545M68 5-pillar Nov 18, 2026
SpyGlass Pharma, Inc. Common Stock (SGP) Same industry, near in market value$30.78 Nov 19, 2026$1.03B64 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$8.14 Nov 19, 2026$796M63 5-pillar Nov 18, 2026
Alzamend Neuro (ALZN) — this page$1.02$4.92M32

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$0.00
EPS estimate
$-2.58

Measured against a quoted price of $1.02 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Aug 26, 2026

Transactions
4
Identified insiders
2
Purchases
0
Sales
1
Other transactions
3

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ALZN in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ALZN in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Alzamend Neuro (ALZN)?

Read these with our analysis →

Alzamend Neuro Stock: Key Questions Answered

These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.

What does the MoonshotScore mean for ALZN?

ALZN carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is ALZN a good stock to buy?

Stock Expert AI does not rate ALZN buy, sell or hold. Alzamend Neuro, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the ALZN stock price today?

The last price recorded for Alzamend Neuro, Inc. (ALZN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the key factors to evaluate for ALZN?

Alzamend Neuro, Inc. (ALZN) holds a MoonshotScore in the low range. Alzamend Neuro, Inc. does not currently pay a dividend, consistent with a growth-focused biopharmaceutical company reinvesting in R&D. Not financial advice.

How frequently does ALZN data refresh on this page?

ALZN's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven ALZN's recent stock price performance?

Alzamend Neuro, Inc. (ALZN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider ALZN overvalued or undervalued right now?

Alzamend Neuro, Inc. (ALZN) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of ALZN?

Fractional-share availability for Alzamend Neuro, Inc. (ALZN) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

How can I track ALZN's earnings and financial reports?

Alzamend Neuro, Inc. (ALZN) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for ALZN earnings announcements.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 6 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.